Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Journal of Biotechnology & Biomaterials received 3330 citations as per Google Scholar report
M. Tino Unlap
Associate Professor
Department of Clinical and Diagnostic Sciences
University of Alabama at Birmingham
USA
Dr Unlap received his PhD in Biochemistry/Molecular Biology from Kansas State University followed by postdoctoral trainings in Oncology and Behavioral Neurobiology under Drs Andrew Kraft and Richard Jope at the University of Alabama at Birmingham studying the roles that immediate early genes play in the pathogenesis of malignancy and neuronal degeneration respectively Dr Unlap was given a faculty appointment in the Department of Medicine where he began his study of the role that the Na/Ca2 exchanger might play in the pathogenesis of salt sensitive hypertension From 19972007 Dr Unlap directed the Heritage Center Biotech Curriculum for high school students and codirected BioTek Works a biotechnology workforce development program funded by Jefferson County and the State of Alabama From 20072008 he was a faculty member at the Tulane Medical School but relocated to help start the University of Alabama at Birmingham Biotechnology Program where he currently serves as a faculty member
There are three main research areas in the lab.The role of the Na+ or Ca2+ exchanger (NCX) in hypertension.We have cloned the NCX from the vasculature of salt sensitive and salt resistant rat and found that they differ by a single base mutation which predisposes the salt sensitive rat to hypertension. We are currently assessing the role that this mutation plays in mediating the effects of oxidative stressin hypertension. The use of antisense technology in treating latent TB.One of the most serious health problems affecting the worlds population is the presence of TB in the latent form where the mycobacterium can hibernate for years and then becomes active and infective. Using molecular beacon technology we are exploring the use of a delivery system which will deliver a molecular beacon antisense RNA against the MCE protein of the mycobacterium which will not only pinpoint the location of the mycobacterium but also eradicate the disease.The use of covalent modifications to Potentiate the effects of anti Parkinson and anticancer drugs.We are currently working on assessing the effects of different covalent modifications of existing drugs for the treatment of Parkinsons disease and cancer.Most modifications tested thus far Potentiate the effects of drugs up to four fold.
A Short Interfering RNA (siRNA) Molecular Beacon for the Detection of Mycobacterial Infection
Remo George, Norman Bolus, Shawn Williams, Joseph Garner, Kathy Nugent and M. Tino Unlap |
Research Article: J Biotechnol Biomater 2012, 2:5 |
DOI: 10.4172/2155-952X.1000147 |
Luay E. Matalka, Ashley Ford and M. Tino Unlap |
Review Article: J Biotechnol Biomater 2012, 2:5 |
DOI: 10.4172/2155-952X.1000144 |
Roger Laine and M. Tino Unlap |
Research Article: J Biotechnol Biomater 2012, 2:5 |
DOI: 10.4172/2155-952X.1000142 |
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals